GYRE (Gyre Therapeutics) EPS (Basic): $-0.08 (TTM As of Mar. 2026)


GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $6.30
GF Value $9.82
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics EPS (Basic)?

Gyre Therapeutics GYRE +1.29% 39 EPS (Basic) is $-0.08 as of Mar. 2026. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Gyre Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.08.

Gyre Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.09.

Gyre Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.08. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.08.

During the past 3 years, the average EPS without NRI Growth Rate was -59.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Gyre Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -59.50% per year. The lowest was -59.50% per year. And the median was -59.50% per year.

Gyre Therapeutics  (NAS:GYRE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Gyre Therapeutics EPS (Basic) Related Terms

Gyre Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics EPS (Basic) Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
0.31 0.03 -1.41 0.14 0.06

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.00 0.04 -0.02 -0.10
GYRE
39GF Score
Gyre Therapeutics Inc GYRE
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Gyre Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(5.027-0)/89.345
=0.06

Gyre Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-8.691-0)/91.317
=-0.10

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.08 mean?
Gyre Therapeutics (GYRE) has a EPS (Basic) of $-0.08 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' EPS (Basic) too high?
Gyre Therapeutics' current EPS (Basic) is $-0.08. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' EPS (Basic) compare to CBIO and RIGL?
Gyre Therapeutics' EPS (Basic) of $-0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current EPS (Basic) is $-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.30 — trading 35.8% below its estimated fair value. The current EPS (Basic) is $-0.08. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current EPS (Basic) is $-0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • EPS (Basic): $-0.08
  • GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.30
Price
$9.82
GF Value